BAUSCH HEALTH COMPANIES WKN: A2JQ1X ISIN: CA0717341071 Kürzel: BHC Forum: Aktien Thema: Hauptdiskussion

Sind doch super news oder?

Ich raff es nicht...

Bausch Health Companies (NYSE:BHC) will pay down an additional $76M of its senior secured term loans next week with cash on hand. The payment will eliminate all mandatory amortization for Q1 2019. Total Q4 debt repayment will be ~$400M

Immerhin an der 20,6 abgeprallt.

Nee, wir haben uns alle unter der Decke verkrochen und warten, bis der Sturm vorüber ist. Aber im Ernst: etwas rätselhaft dieser massive Fall. Das letzte Gefecht der Shorties? Das Volumen ist ja nicht sehr hoch

Gab's heute wieder was negatives oder wieder Gewinnmitnahmen auf Jahressicht. Noch jemand dabei? ;)

Hmmm... Auf Jahressicht nun aber unter die untere trendlinie gerutscht.

Bin dieses Jahr echt zufrieden hier, Mal eine Aktie im Plus auf Jahresicht!!!

Ja da weiss man auch wer zu den LV gehört...

Ganz krass , nach dem heutigen massiven Upgrade versucht doch gleich wieder dieser ver......... Maris uns mit Johnson&Johnson in den Dreck zu ziehen

Ich sag's immer wieder: hier kann der Anstieg nur verzögert, aber nicht verhindert werden

Brrr.. Sowas erinnert mich an meine ströer akiten vor einiger Zeit :/ aber nun machen wir schön wochenende

Die erhöhten Kursziele gefallen halt nicht allen, und bei dem geringen Volumen heute kann die LV-Fraktion schon mit kleinerem Einsatz etwas bewegen. Wells Fargo grätscht ja auch wieder rein

Erst eine target Anpassung von 25 auf 58 Dollar und nun...

Was geht jetzt denn noch ab....

Bausch Health Companies IncSymbolC : BHCShares Issued349,757,253Close 2018-12-11C$ 30.91Recent Sedar Documents   View Original Document Bausch Health to acquire Synergy Pharma for $200M 2018-12-12 06:50 ET - News Release Mr. Joseph Papa reports BAUSCH HEALTH ENTERS INTO DEFINITIVE "STALKING HORSE" AGREEMENT TO ACQUIRE SUBSTANTIALLY ALL THE ASSETS OF SYNERGY PHARMACEUTICALS INC. Bausch Health Companies Inc. has entered into a definitive agreement to acquire certain assets of Synergy Pharmaceuticals Inc. in a transaction valued at approximately $200-million plus certain assumed liabilities. Synergy filed a voluntary petition for reorganization under Chapter 11 of the U.S. Code with the U.S. Bankruptcy Court for the Southern District of New York earlier today. Under the terms of the agreement, and subject to Bankruptcy Court approval, Bausch Health will serve as the stalking horse bidder in a court-supervised auction and sale process, which Synergy will conduct pursuant to Section 363 of the Bankruptcy Code. Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. Synergy's flagship product, Trulance (plecanatide) is a once-daily tablet approved for adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). "The acquisition of the assets of Synergy will enhance our Salix Pharmaceuticals business. We believe Trulance is a natural complement to Xifaxan (rifaximin), and with the scale and strength of our sales footprint in GI and primary care, our Salix team will be able to offer physicians and patients multiple treatment options that span the types of irritable bowel syndrome. Furthermore, adding Synergy's investigational dolcanatide to our pipeline will provide an incremental peptide with established proof-of-concept studies in multiple GI conditions," said Joseph C. Papa, chairman and chief executive officer, Bausch Health. "As part of our transformation strategy, we will continue to seek strategic bolt-on opportunities that we believe will help drive long-term growth in our core businesses and for the company." Agreement details Under the terms of the definitive stalking horse agreement, Bausch Health (through its affiliate) has agreed to acquire most of Synergy's assets, including intellectual property, customer and vendor contracts, accounts receivable and goodwill, free and clear of liabilities except certain expressly assumed liabilities. Additionally, Bausch Health has committed to make employment offers to a number of the sales and commercial employees of Synergy. As part of the sale process, Bausch Health's bid is subject to higher or better offers, as other interested parties will have an opportunity to submit competing bids. Bausch Health does not require any financing to complete the acquisition. If Bausch Health's bid is successful, the transaction is expected to close in the first quarter of 2019, subject to customary closing conditions and approval of the Bankruptcy Court. Wachtell, Lipton, Rosen & Katz served as legal adviser to Bausch Health in this transaction. About Xifaxan Xifaxan (rifaximin) 550-milligram tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults and for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. Important safety information: Xifaxan is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in Xifaxan. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema and anaphylaxis. Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Xifaxan, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, continuing antibiotic use not directed against C. difficile may need to be discontinued. There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering Xifaxan to these patients. Caution should be exercised when concomitant use of Xifaxan and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. In clinical studies, the most common adverse reactions for Xifaxan in IBS-D (equals 2 per cent) were nausea (3 per cent) and ALT increased (2 per cent). In clinical studies, the most common adverse reactions for Xifaxan in HE (equals 10%) were peripheral edema (15 per cent), nausea (14 per cent), dizziness (13 per cent), fatigue (12 per cent) and ascities (11 per cent). INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required. Xifaxan may cause fetal harm. Advise pregnant women of the potential risk to a fetus. To report suspected adverse reactions, contact Salix Pharmaceuticals at 1-800-321-4576. About Bausch Health Companies Inc. Bausch Health is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. It is delivering on its commitments as it build an innovative company dedicated to advancing global health. We seek Safe Harbor. © 2018 Canjex Publishing Ltd. All rights reserved